QHSLab doubles assessment completions to ~50K year-to-date; two abstracts accepted at ACAAI

QHSLab, Inc.

Platform processed ~50,000 assessments in 2024 YTD, more than double the same period in 2023.
Two abstracts accepted for presentation at ACAAI conference in Boston; two more submitted for 2025 APA meeting.
R&D focusing on AI-driven digital tools for allergic rhinitis, anxiety, depression, chronic pain.
Preliminary findings from health journeys series show reduced depression, anxiety, pain, allergy scores after few months.
Company continues to integrate digital medicine to reduce non-clinical burden on providers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.